Trial ChiCTR2100051998
Publication Cao Y, Cell Res, 2021
Primary outcome on the report: Seroconversion rate on day 14 after the third dose of neutralizing antibodies to authentic SARS-CoV-2, which was defined as a change of titers from seronegative at baseline to seropositive, or a four-fold increase of titers for individuals whose titers were above seropositive cutoffs (1:8).

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.